Abstract:

Objective　To investigate the clinical effect of pantoprazole sodium combined with alprostadil for patients with severe acute pancreatitis (SAP) and its influence on levels of amylase (AMY), alanine aminotransferase (ALT), and creatinine (Cr). Methods　Seventy-four patients with SAP diagnosed and treated in Xincai County People's Hospital from June 2019 to January 2020 were selected and divided into a control group and a study group according to the standard of randomization, with 37 patients in each group. There were 25 males and 12 females in the control group; they were (47.5±2.1) years old. There were 24 males and 13 females in the observation group; they were (47.1±2.2) years old. The control group were treated with pantoprazole sodium, and the study group with pantoprazole sodium and alprostadil. The levels of relevant indicators for restoring gastrointestinal function were compared between the two groups. The serum levels of ALT, AMY, and Cr before and after the treatment were compared between the two groups. The scores of acute physiology and chronic health evaluation (APACHE-Ⅱ) at different time points after the treatment were compared between the two groups. t and χ² were applied. Results　The clinical treatment efficacy of the study group was higher than that of the control group [81.08% (30/37) vs. 54.05% (20/37)], with a statistical difference between the two groups (P<0.05). The recovery times of relevant indicators of gastrointestinal function in the study group were shorter than those in the control group (all P<0.05). The serum levels of ALT, AMY, and Cr in the study group were significantly lower than those in the control group (all P<0.05). The APACHE-Ⅱ scores at different time points after the treatment in the study group were significantly lower than those in the control group (all P<0.05). The incidence of adverse reactions in the study group was lower than that in the control group, but with no statistical difference (P>0.05). Conclusions　The combination of pantoprazole sodium and alprostadil for patients with SAP can significantly shorten the time for them to recover gastrointestinal function, and reduce their levels of AMY, ALT, and Cr and the APACHE-Ⅱ score. The clinical effect is significant, and the adverse reaction rate is lower. Therefore, it is worth being generalized.

Key words:

Severe acute pancreatitis, Pantoprazole sodium, Alprostadil, Clinical effect

摘要：

目的　探讨泮托拉唑钠联合前列地尔治疗重症急性胰腺炎（SAP）患者的临床效果及对血清丙氨酸氨基转移酶（ALT）、淀粉酶（AMY）及肌酐（Cr）水平的影响。方法　选取2019年6月至2020年1月在新蔡县人民医院确诊并治疗的74例SAP患者，遵照随机分组标准分为对照组和研究组，每组37例。对照组中，男25例、女12例，年龄（47.5±2.1）岁，应用泮托拉唑钠治疗；研究组中，男24例、女13例，年龄（47.1±2.2）岁，应用泮托拉唑钠联合前列地尔治疗。观察比较两组恢复胃肠功能的相关指标水平差异；比较两组患者治疗前后的血清ALT、AMY及Cr水平，治疗后不同时间点的急性生理学和慢性健康评价（APACHE-Ⅱ）评分差异。采用t检验、χ²检验进行统计分析。结果　研究组临床治疗有效率为81.08%（30/37），对照组为54.05%（20/37），两组比较差异有统计学意义（P<0.05）。研究组恢复胃肠功能的相关指标水平时间均短于对照组（均P<0.05）。研究组治疗后的血清ALT、AMY及Cr水平均显著低于对照组（均P<0.05）。研究组治疗后不同时间点的APACHE-Ⅱ评分均显著低于对照组（均P<0.05）。研究组不良反应发生率小于对照组，但差异无统计学意义（P>0.05）。结论　SAP患者联合使用泮托拉唑钠及前列地尔治疗可显著缩短恢复胃肠功能的时间，降低AMY、ALT、Cr水平及APACHE-Ⅱ评分，临床效果显著，且不良反应率低，值得推广。

关键词:

重症急性胰腺炎, 泮托拉唑钠, 前列地尔, 临床效果